CDK clinical trial results, benefit, side effects and costs

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting

Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers

Coming of age for CDK 4/6 inhibitors: Interactive session and close

Biomarkers of sensitivity and resistance

Editor's ESMO 2016 roundup

Abiraterone in patients with recurrent epithelial ovarian cancer

Fatigue in men with castration resistant prostate cancer treated with enzalutamide

PDL-1 assay concordance

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

CDK4/6 inhibitors for metastatic breast cancer